Cargando…
Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection
BACKGROUND: Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs clinical trials. CASE PRESENTATION: We present a case of an...
Autores principales: | Husnain, Muhammad, Park, Wungki, Ramos, Juan Carlos, Johnson, Thomas E., Chan, Joseph, Dasari, Arvind, Mudad, Raja, Hosein, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036694/ https://www.ncbi.nlm.nih.gov/pubmed/29986769 http://dx.doi.org/10.1186/s40425-018-0379-x |
Ejemplares similares
-
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021) -
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019) -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022) -
Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)